Summary
The product Anadrol 25mg/tab, manufactured by REDMOND PHARMACY, underwent independent testing to verify its authenticity and potency. The sample, identified by batch number 120410, was submitted by REDMOND PHARMACY and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the presence of Oxymetholone, with a concentration of 30.26 mg per tablet, exceeding the labeled claim of 25 mg by 21.04%.
The testing process was conducted on 08 OCT 2024. While the results confirm accurate dosing, further independent validation is recommended to ensure consistency across the product line. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: REDMOND PHARMACY
- Product Name: Anadrol 25mg/tab
- Active Ingredient: Oxymetholone
- Batch Number: 120410
- Expiration Date: Not provided
- Delivery Method: Oral
Sample Acquisition and Testing
- Task Number: #50049
- Testing Ordered: 27 September 2024
- Sample Received: 3 October 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Redmond Pharmacy (Manufacturer)
- Analysis Paid For By: Redmond Pharmacy (Manufacturer)
Testing Results
- Oxymetholone Concentration: 30.26 mg per tablet
- Accuracy: 121.04% (21.04% above the label claim)
- Variance: 21.04%
Verification Details
- Verification URL: https://janoshik.com/tests/50049_K61JPHQR4YJX
Evaluation of Manufacturer-Submitted Testing
This analysis highlights the accuracy of the tested product, with a measured concentration of 30.26 mg per tablet, exceeding the labeled claim by 21.04%. However, manufacturer-submitted samples may not fully represent the consistency of products available in the broader market. Independent third-party testing remains crucial to validate these findings comprehensively.
Conclusion
The analysis confirms that Anadrol 25mg/tab is significantly overdosed, with a measured concentration of 30.26 mg per tablet. This result reflects strong quality control for this batch but underscores the importance of additional testing to ensure consistent dosing across the product line. This report is provided to support educational and harm reduction efforts, helping consumers make informed choices regarding anabolic steroid products.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
